Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Yi Yang

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 27, 2025
Metformin-Based Covalent Organic Frameworks With Excellent Biosafety and High Efficiency against Pathogenic MicroorganismsJia-Yi Liu, Hong Jiang, Lei Ma, et al.
Journal of the American Chemical Society|September 4, 2024
3D Covalent Organic Frameworks with 16-Connectivity for Photocatalytic C(sp<sup>3</sup>)-C(sp<sup>2</sup>) Cross-CouplingMeng Lu, Shuai-Bing Zhang, Run-Han Li, et al.
Molecular Carcinogenesis|April 17, 2023
Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancerXiao-Rong Yang, Can Pi, Yi-Chen Zhang, et al.
Journal for Immunotherapy of Cancer|July 18, 2023
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancerJia-Yi Deng, Qing Gou, Lingling Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Oncoimmunology|April 11, 2024
Redox<sup>high</sup> phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinomaXue-Wu Wei, Chang Lu, Yi-Chen Zhang, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Journal of Translational Medicine|April 2, 2024
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancerWei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, et al.
Eclinicalmedicine|October 2, 2023
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 27, 2025
Metformin-Based Covalent Organic Frameworks With Excellent Biosafety and High Efficiency against Pathogenic MicroorganismsJia-Yi Liu, Hong Jiang, Lei Ma, et al.
Journal of the American Chemical Society|September 4, 2024
3D Covalent Organic Frameworks with 16-Connectivity for Photocatalytic C(sp<sup>3</sup>)-C(sp<sup>2</sup>) Cross-CouplingMeng Lu, Shuai-Bing Zhang, Run-Han Li, et al.
Molecular Carcinogenesis|April 17, 2023
Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancerXiao-Rong Yang, Can Pi, Yi-Chen Zhang, et al.
Journal for Immunotherapy of Cancer|July 18, 2023
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancerJia-Yi Deng, Qing Gou, Lingling Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Oncoimmunology|April 11, 2024
Redox<sup>high</sup> phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinomaXue-Wu Wei, Chang Lu, Yi-Chen Zhang, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Journal of Translational Medicine|April 2, 2024
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancerWei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, et al.
Eclinicalmedicine|October 2, 2023
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, et al.
Pageof 3